Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

2011912 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 12, Issue 5, pp. 431-440

Field-Weighted Citation Impact: 49.30